Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Imatinib AND Glivec

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    128 result(s) found for: Imatinib AND Glivec. Displaying page 2 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2012-001355-38 Sponsor Protocol Number: AP24534-12-301 Start Date*: 2012-10-04
    Sponsor Name:ARIAD Pharmaceuticals, Inc
    Full Title: A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
    Medical condition: Chronic Myeloid Leukemia in Chronic Phase
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed) SE (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002749-37 Sponsor Protocol Number: ISAV Start Date*: 2011-10-11
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA
    Full Title: Validation of digital-PCR analysis through programmed imatinib interruption in PCR negative chronic myeloid leukemia patients.
    Medical condition: Chronic Myeloid Leukemia (CML) with substained Complete Molecular Response (CMR).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) DE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002600-41 Sponsor Protocol Number: CSTI571H2201 Start Date*: 2006-01-17
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que no reciben fármacos anti...
    Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019014-25 Sponsor Protocol Number: Istrokepilot Start Date*: 2010-07-27
    Sponsor Name:Karolinska University Hospital
    Full Title: A PROSPECTIVE, RANDOMISED, OPEN, BLINDED EVALUATION, ASCENDING-DOSE, PILOT TRIAL OF IMATINIB IN ACUTE ISCHAEMIC STROKE (I-STROKE/pilot)
    Medical condition: Acute ischaemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002267-11 Sponsor Protocol Number: CAMN107A2201 Start Date*: 2006-11-10
    Sponsor Name:Novartis Pharma Services
    Full Title: A randomized, open-label,multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intolera...
    Medical condition: Gastrointestinal stromal tumors (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004063-29 Sponsor Protocol Number: CSTI571BDE40 Start Date*: 2004-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients
    Medical condition: Glioblastoma multiforme/astrocytoma WHO grade IV, with progression on temozolomide containing regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007054-35 Sponsor Protocol Number: CAMN107A2404 Start Date*: 2009-08-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Medical condition: IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-007091-15 Sponsor Protocol Number: CSTI571ENL18 Start Date*: 2007-09-03
    Sponsor Name:ErasmusMC
    Full Title: Glivec (imatinib mesylate) in systemic sclerosis, a pilot study
    Medical condition: systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002603-16 Sponsor Protocol Number: CSTI571H2202 Start Date*: 2006-01-17
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio fase II, abierto, multicéntrico, no comparativo, que evalúa la eficacia de Glivec® con Hidroxiurea en pacientes con Glioblastoma Multiforme (GBM) en progresión, que reciben fármacos anticon...
    Medical condition: Glioblastoma multiforme progresivo (GBM) tras fallo a terapia de primera línea definida por cirugía, radioterapia y exposición a un régimen de quimioterapia de Temozolamida (TMZ).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) DE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001044-38 Sponsor Protocol Number: UMCN-AKF14.01 Start Date*: 2014-07-28
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Influence of an Acidic Beverage (Coca-Cola) on the exposure to Imatinib (GLIvec) after major gastrecTomY in patients with Gastrointestinal Stromal Tumors (ABILITY)
    Medical condition: Patients who are treated or will be treated with imatinib, who previously underwent major gastrectomy.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001396-19 Sponsor Protocol Number: CSTI571 0109 Extension2 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acut...
    Medical condition: Philadelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001397-92 Sponsor Protocol Number: CSTI571 0110 Extension2 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha
    Medical condition: Philadelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003774-40 Sponsor Protocol Number: TheStopGISTtrial Start Date*: 2016-11-09
    Sponsor Name:Oslo University Hospital
    Full Title: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment
    Medical condition: Gastrointestinal stromal tumour (GIST)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004761-28 Sponsor Protocol Number: GEIS41 Start Date*: 2019-06-20
    Sponsor Name:Grupo Español de Investigación en Sarcomas
    Full Title: A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs)
    Medical condition: Gastrointestinal stromal tumor (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006119-22 Sponsor Protocol Number: FARM6HJ7CA Start Date*: 2008-03-25
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours (TET) or Histiocitosi X (LCH) with Imatinib Mesylate.
    Medical condition: Patients affected by TET or LCH
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003451-20 Sponsor Protocol Number: TUD-Glivec-012 Start Date*: 2007-03-16
    Sponsor Name:Technical University Dresden
    Full Title: Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct
    Medical condition: advanced carcinoma of the gallbladder and bile duct
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001810-16 Sponsor Protocol Number: 62024 Start Date*: 2004-11-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versu...
    Medical condition: Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018339-16 Sponsor Protocol Number: CSTI571ADE75T-GMIHO-005/2009 Start Date*: 2010-07-19
    Sponsor Name:GMIHO mbH
    Full Title: CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-p...
    Medical condition: CML - chronic myelogenous leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004384-19 Sponsor Protocol Number: GIMEMA CML0408 Start Date*: 2008-07-29
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Front-line treatment of Philadelphia positive (Ph pos), BCR-ABL positive, chronic myeloid leukemia (CML) with two tyrosine kinase inhibitors (TKI) (Nilotinib and Imatinib). A phase II exploratory m...
    Medical condition: Philadelphia positive (Ph pos), BCR-ABL positive, Chronic Myeloid Leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005101-31 Sponsor Protocol Number: AV001 Start Date*: 2014-06-17
    Sponsor Name:Pfizer Inc
    Full Title: A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
    Medical condition: Chronic Myeloid Leukemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) SE (Completed) CZ (Completed) HU (Completed) SK (Completed) FI (Completed) NO (Completed) ES (Completed) DK (Completed) NL (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 08 02:31:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA